当前位置: X-MOL 学术Adv. Funct. Mater. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hesperetin Nanoparticle Targeting Neutrophils for Enhanced TBI Therapy
Advanced Functional Materials ( IF 18.5 ) Pub Date : 2022-08-08 , DOI: 10.1002/adfm.202205787
Kai Yao 1 , Qingchun Mu 2 , Yufei Zhang 3 , Qian Cheng 3 , Xiaozhi Cheng 2 , Xiaojing Liu 2 , Chunmei Luo 2 , Chumei Li 2 , Shuxia Cai 2 , Zhicheng Luo 2 , Xiulong Zhu 2 , Xiangtong Zhang 1 , Liao Cui 4 , Chunming Huang 2 , Longguang Tang 2, 5
Affiliation  

Traumatic brain injury (TBI) is the main cause of death and disability in people of all ages worldwide. Neuroinflammation plays beneficial and harmful roles in secondary brain injury. Neutrophils play an important role in chemically mediated inflammatory responses through myeloperoxidase (MPO) and inflammation triggered by TBI. Herein, a nanodrug targeting neutrophils and MPO through chemical and biological functions after TBI is designed to enhance the retention and sustained release of drug cargos for improved TBI therapy. 5-Hydroxytryptamide (5-HT) is modified on nanoparticles (NPs) loaded with an anti-inflammatory and antioxidant natural product, hesperetin, to obtain MPO- and neutrophil-targeting NPs, denoted as T-Hes. In a mouse TBI model, it is confirmed that neutrophil-targeting NPs can quickly accumulate and remain in the brain tissue, reduce the secretion of inflammatory factors, and the level of microglia and astrocytes, subsequently inducing the transformation of microglia from pro-inflammatory M1 to anti-inflammatory M2 cells and promoting the infiltration of regulatory T cells (Tregs). T-Hes significantly inhibits neuroinflammation and improves neurological deficits through the sustained release of hesperetin in the brain. The findings may open up new avenues for designing clinically translatable probes for TBI treatment.

中文翻译:

橙皮素纳米颗粒靶向中性粒细胞用于增强 TBI 治疗

创伤性脑损伤 (TBI) 是全球所有年龄段人群死亡和残疾的主要原因。神经炎症在继发性脑损伤中起着有益和有害的作用。中性粒细胞通过髓过氧化物酶 (MPO) 和 TBI 引发的炎症在化学介导的炎症反应中发挥重要作用。在此,一种通过 TBI 后的化学和生物功能靶向中性粒细胞和 MPO 的纳米药物旨在增强药物货物的保留和持续释放,以改善 TBI 治疗。5-羟基色胺 (5-HT) 在负载有抗炎和抗氧化天然产物橙皮素的纳米颗粒 (NPs) 上进行修饰,以获得 MPO 和中性粒细胞靶向 NPs,表示为 T-Hes。在小鼠 TBI 模型中,证实中性粒细胞靶向 NPs 可以快速积聚并保留在脑组织中,减少炎症因子的分泌,以及小胶质细胞和星形胶质细胞的水平,随后诱导小胶质细胞从促炎性 M1 细胞向抗炎性 M2 细胞转化,并促进调节性 T 细胞 (Tregs) 的浸润。T-Hes 通过在大脑中持续释放橙皮素,显着抑制神经炎症并改善神经功能缺损。这些发现可能为设计用于 TBI 治疗的临床可翻译探针开辟新途径。T-Hes 通过在大脑中持续释放橙皮素,显着抑制神经炎症并改善神经功能缺损。这些发现可能为设计用于 TBI 治疗的临床可翻译探针开辟新途径。T-Hes 通过在大脑中持续释放橙皮素,显着抑制神经炎症并改善神经功能缺损。这些发现可能为设计用于 TBI 治疗的临床可翻译探针开辟新途径。
更新日期:2022-08-08
down
wechat
bug